Prospective Population Study on Candidemia in Spain

Prospective Population Study on Candidemia in Spain (Estudio Poblacional Prospectivo Sobre Candidemia en España)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01236261

Acronym

CANDIPOP

Enrollment

730

Registered

2010-11-08

Start date

2013-03-31

Completion date

2013-03-31

Last updated

2013-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fungemia

Keywords

Fungemia, fungal infection, susceptibility, antifungal

Brief summary

The aim of this study is to describe the epidemiology of fungal blood infections in Spain (with emphasis on the incidence, fungal species distribution and antifungal susceptibility). The study is to be performed in five big cities which represent different geographic areas: Barcelona, Bilbao, Madrid, Sevilla and Valencia.

Interventions

OTHERNon intervention

Non interventional study

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Fungal isolate obtained from blood sample

Exclusion criteria

* None

Design outcomes

Primary

Measure	Time frame	Description
Describe fungemia epidemiology in Spain	1 year	Recollection of demographic variables (age, gender and ethnic origin); clinical variables (background diseases, other coinfections, treatment received, etc) and microbiological information of the isolate.

Secondary

Measure	Time frame	Description
Describe differences among cities and institutions	1 year	Analyze results in function of the city and hospital where the isolate was obtained (5 cities in Spain and 29 participating hospitals)
Definition of risk factors	1 year	Determine risk factors for: * bad clinical evolution * infection by a specific Candida species * fluconazole resistant isolate * fungemia persistency
Determination of the fungal isolates susceptibility to fluconazole, voriconazole, caspofungine, anidulafungine, micafungine and anfotericine B	1 year	Analysis of resistant strains percentage according to the threshold established by CLSI to each specific antifungal
Correlation between fungemia with a diminished susceptibility fungal strain and clinical evolution	1 year	Chi-square and Kaplan-Meier survival curves
Correlation between reference and commercial microbiological methods	1 year	Comparison of results when a reference or a commercial fungal identification and antifungal susceptibility method is used.

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 2, 2026